WO2005048738A1 - Use of cassia sophera and its aqueous extract for producing foods of reducing symptom of diabetic - Google Patents

Use of cassia sophera and its aqueous extract for producing foods of reducing symptom of diabetic Download PDF

Info

Publication number
WO2005048738A1
WO2005048738A1 PCT/CN2003/001011 CN0301011W WO2005048738A1 WO 2005048738 A1 WO2005048738 A1 WO 2005048738A1 CN 0301011 W CN0301011 W CN 0301011W WO 2005048738 A1 WO2005048738 A1 WO 2005048738A1
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic
effect
weeks
drinking
aqueous extract
Prior art date
Application number
PCT/CN2003/001011
Other languages
French (fr)
Chinese (zh)
Inventor
Xingbo Feng
Original Assignee
Xingbo Feng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xingbo Feng filed Critical Xingbo Feng
Priority to PCT/CN2003/001011 priority Critical patent/WO2005048738A1/en
Priority to CNA2003801102568A priority patent/CN1764390A/en
Priority to AU2003289600A priority patent/AU2003289600A1/en
Publication of WO2005048738A1 publication Critical patent/WO2005048738A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention belongs to the field of food use of Chinese medicine.
  • Anemone (Cassia sophera Linn.), A medicinal plant, Cassia spp.
  • Amaranth also known as Amaranth Cassia, is flat, non-toxic, and has a sweet taste. It has the effect of removing phlegm and thirst, making people sleepless, and regulating the effect. It is also known as Antipyretics. Alcoholic extracts from the leaves of Mang Mangosteen have the effect of relaxing the small intestine and bronchial smooth muscle of guinea pigs.
  • the purpose of the present invention is to prepare foods that improve the symptoms of diabetes by using mangosteen and its water extract.
  • the water extraction method is as follows:
  • Frying method Water is used as the solvent, and the effective ingredients are extracted by heating and boiling. Generally, it must be extracted 2-4 times. The amount of solvent is generally 6-20 times the amount of awn.
  • Immersion method Cold soaking or warm soaking of amaranth for a large number of solvents, and after the ingredients are dissolved and equilibrated, the extraction solution is directly released.
  • Ultrasonic extraction method After soaking the awns, put them into ultrasonic waves together with the solvent, and use the effect of ultrasound to dissolve the awns.
  • Microwave extraction method Put the awn and the solvent in the microwave together, and use the microwave to polarize the molecules to dissolve the components.
  • the present invention When used to prepare foods for treating diabetes and improving symptoms, it can be made into teabags or added to foods or beverages, and its water extract can be added with conventional excipients to make oral liquids, tablets, and capsules. Or pills.
  • the food prepared by the present invention for treating diabetes and improving the symptoms thereof is made of sassafras or its water extract together with auxiliary substances, edible additives or flavors that are beneficial to the human body.
  • the auxiliary substances may be starch-like substances such as Rice and noodles; auxiliary substances can also be oligosaccharides, spirulina, hawthorn, carrot gravy, vitamins, zinc gluconate, dextrin and other substances; edible additives that are good for the human body can be other food additives Chinese medicinal materials or western medicine; the flavoring agent may be a functional sweetener, a flavor enhancer, a flavor, a compound such as a cyclodextrin and the like.
  • the dose of effective substance can be changed according to the way of taking, the age and weight of the patient, the severity of the disease and other similar factors.
  • the oral dose is 10.0-15.0mg / kg, twice daily.
  • the food of the invention has better effects of lowering blood sugar, treating diabetes and improving symptoms. Under the condition of normal diet, patients can consciously maintain blood sugar stability, obtain non-drug treatment effects of diabetes, and solve nutritional balance and metabolism problems of patients with diabetes.
  • test examples include pharmacodynamic tests and clinical efficacy observation tests.
  • Test example 1 Effect of limulus mandshurica extract on hyperglycemic animal model in Wistar rats 1.1 Test materials
  • JPS-III fast blood glucose tester produced by Beijing Yicheng Bioelectronic Technology Co., Ltd.
  • Wistar rats Since the introduction of Wistar rats by the Animal Department of Jilin University, they have been kept in the animal room of the Basic Medical College of Jilin University, room temperature 22-25 ° C, humidity 30-60%, feed composition: corn meal 39%, bean cake noodle 25%, wheat bran noodle 14 %, Sorghum noodles 10%, bone meal 2.5%, fish meal 5%, yeast 3.5%, and additives 1%.
  • the groups are: normal control group, model group, Xiaoke Wan group 2.0g / kg, which is equivalent to 4 times the clinical dosage; mango extract large dose group 0.62g / kg, medium dose group 0.31g / kg, low dose group 0.15g / kg, equivalent to 8, 4, or 2 times the clinical dosage.
  • the model group was given 10 ml / kg of water, and each administration group was given 10 ml / kg of test solution. Gavage is administered around 9am every day for four consecutive weeks. Blood glucose and body weight are measured weekly, and the dose is calculated once based on the new weight. Animals were sacrificed after the fourth week of administration, blood tests were performed for blood routine, blood biochemical indicators, blood rheology and insulin content, and pancreas were taken for histopathological examination. The results obtained by each group are represented by the mean ( ⁇ ) soil standard deviation (S), and the results are compared with the model group to perform a t-test between the groups to determine their significance. 1.3 Test results
  • Test Example 2 Clinical observation of the food of the present invention in the treatment of diabetic patients 2.1-General information See Table 2 Table 2
  • the diabetic patients drink the invention the longer the drinking time, the more obvious the effect, that is, drinking for one week is basically ineffective, drinking for two weeks shows a hypoglycemic effect, drinking for three weeks has a significant hypoglycemic effect, and drinking for four weeks is extremely significant .
  • the 23 diabetes patients drinking the invention in Table 1 were divided into two groups: those with disease for more than 5 years as a group, those with disease for less than 4 years as a group, and statistical analysis was performed, and the results were as follows:
  • Table 8 shows the analysis of drinking effects for patients under 4 years of illness.
  • Amaranth has a significant effect on reducing blood sugar in patients with diabetes.
  • Diabetic patients can take two weeks to drink it, and the effect is obvious around four weeks.
  • the illness time is shorter (less than 4 years) and longer than that (more than 5 years).
  • a health-care oral liquid containing mangosteen water extract to improve the symptoms of diabetes 2.0g of mangosteen water extract, 10000ml of water, mixed into 100 bottles, each 100ml, containing 20mg of mangosteen extract .
  • Mangosteen 20.0g, kudingcha was pulverized into 4980g of L5 ⁇ 2mm pieces, and the two were thoroughly mixed and put into a food bag to make 500 bags. Each bag weighed 10g and contained mangosteen 40mg.
  • Water extract of mangosteen 10g mixed with 1000L of prickly pear juice and packed into 1000 bottles, 1L per bottle, each bottle contains 10mg of water extract from mangosteen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a use of cassia sophera and its aqueous extract for producing foods of reducing symptom of diabetic, being for making foods from Chinese traditional medicine. The invention possesses the obvious action for reducing blood sugar of diabetic. As long as diabetics take the food of the invention, the action is detectable after two weeks, then it is obvious after four weeks, thereby the cassia sophera and its aqueous extract are preferable for producing foods of reducing symptom of diabetic.

Description

茳芒及其提取物在制备改善糖尿病症状的食品中的应用 技术领域  Application of mangosteen and its extract in preparing food for improving diabetes symptoms Technical field
本发明属于中药的食品用途领域。  The invention belongs to the field of food use of Chinese medicine.
背景技术 Background technique
茳芒 ( Cassia sophera Linn. ), 药用植物, 豆科苏木亚科决明属。 据《中药大辞典》中记载: "茳芒, 又称茳芒决明, 性平, 无毒, 味 甘滑。 具有除痰止渴, 令人不睡, 调中的功效。 又称其为解热药。 茳芒 叶的醇提物有松弛豚鼠小肠、支气管平滑肌的作用。"本发明中是指的是 茳芒子。  Anemone (Cassia sophera Linn.), A medicinal plant, Cassia spp. According to the "Traditional Chinese Medicine Dictionary": "Amaranth, also known as Amaranth Cassia, is flat, non-toxic, and has a sweet taste. It has the effect of removing phlegm and thirst, making people sleepless, and regulating the effect. It is also known as Antipyretics. Alcoholic extracts from the leaves of Mang Mangosteen have the effect of relaxing the small intestine and bronchial smooth muscle of guinea pigs.
发明内容 Summary of the invention
本发明的目的就是应用茳芒及其水提取物制备改善糖尿病症状的食 品。  The purpose of the present invention is to prepare foods that improve the symptoms of diabetes by using mangosteen and its water extract.
其水提物采用水提方法为:  The water extraction method is as follows:
1.煎煮法: 以水为溶媒, 加热煮沸提取有效成分, 一般须提取 2-4 次, 溶媒用量一般为茳芒量的 6-20倍。  1. Frying method: Water is used as the solvent, and the effective ingredients are extracted by heating and boiling. Generally, it must be extracted 2-4 times. The amount of solvent is generally 6-20 times the amount of awn.
2.渗漉法: 为茳芒经冷浸泡或温浸泡后, 以适当温度的溶媒, 流经 茳芒, 以溶出茳芒之成分。  2. Infiltration method: After cold soaking or warm soaking, the mango is passed through the mango with a solvent at an appropriate temperature to dissolve the components of the mango.
3.浸渍法: 为大量溶媒冷浸泡或温浸泡茳芒, 待成分溶出平衡后, 直接放出提取液。  3. Immersion method: Cold soaking or warm soaking of amaranth for a large number of solvents, and after the ingredients are dissolved and equilibrated, the extraction solution is directly released.
4.超声提取法: 为茳芒经浸泡后, 与溶媒一起置超声波中, 利用超 声波的效应, 使茳芒成分溶出。  4. Ultrasonic extraction method: After soaking the awns, put them into ultrasonic waves together with the solvent, and use the effect of ultrasound to dissolve the awns.
1 1
更正页(细则第 91条) 5.微波提取法: 将茳芒与溶媒一同置微波中, 利用微波使分子极化, 而使其成分溶出。 Correction page (Article 91) 5. Microwave extraction method: Put the awn and the solvent in the microwave together, and use the microwave to polarize the molecules to dissolve the components.
当本发明用于制备治疗糖尿病及改善其症状的食品时, 可以制成袋 泡茶, 或添加于食品或饮料中, 其水提取物可加常规赋形剂制成口服液、 片剂、 胶囊或丸剂。  When the present invention is used to prepare foods for treating diabetes and improving symptoms, it can be made into teabags or added to foods or beverages, and its water extract can be added with conventional excipients to make oral liquids, tablets, and capsules. Or pills.
本发明制备治疗糖尿病及改善其症状的食品是由茳芒子或其水提取 物与辅助物质、 有益于人体的可食用的添加剂或风味剂一起制成的, 辅 助物质可以是淀粉类物质, 如米和面; 辅助物质还可以是低聚糖类、 螺 旋藻、 山楂、 胡萝卜肉汁、 维生素、 葡萄糖酸锌、 糊精等物质; 有益于 人体的可食用的添加剂可以是其它可添加于食品中的中药材或西药; 风 味剂可以是功能性的甜味剂, 增味剂、 香精香料、 环糊精等复合物。  The food prepared by the present invention for treating diabetes and improving the symptoms thereof is made of sassafras or its water extract together with auxiliary substances, edible additives or flavors that are beneficial to the human body. The auxiliary substances may be starch-like substances such as Rice and noodles; auxiliary substances can also be oligosaccharides, spirulina, hawthorn, carrot gravy, vitamins, zinc gluconate, dextrin and other substances; edible additives that are good for the human body can be other food additives Chinese medicinal materials or western medicine; the flavoring agent may be a functional sweetener, a flavor enhancer, a flavor, a compound such as a cyclodextrin and the like.
有效物质的剂量可以根据服用方式, 病人的年龄和体重及病情严重 程度和其它类似的因素而改变,口服量为: 10.0-15.0mg/kg,每日二次服用。  The dose of effective substance can be changed according to the way of taking, the age and weight of the patient, the severity of the disease and other similar factors. The oral dose is 10.0-15.0mg / kg, twice daily.
本发明食品具有较好的降低血糖、治疗糖尿病及其改善症状的效果。 使患者在正常饮食的情况下, 自觉地维护血糖稳定, 获得糖尿病的非药 物治疗效果, 解决好糖尿病患者的营养平衡和代谢问题。  The food of the invention has better effects of lowering blood sugar, treating diabetes and improving symptoms. Under the condition of normal diet, patients can consciously maintain blood sugar stability, obtain non-drug treatment effects of diabetes, and solve nutritional balance and metabolism problems of patients with diabetes.
具体实施方式 detailed description
以下通过试验例来进一步阐述应用本发明制备所述食品的有益效 果, 这些试验例包括了药效学试验和临床疗效观察试验。  The beneficial effects of the food prepared by the application of the present invention are further explained through test examples. These test examples include pharmacodynamic tests and clinical efficacy observation tests.
试验例 1 茳芒提取物对 Wistar大鼠高血糖动物模型的影响 1.1试验材料  Test example 1 Effect of limulus mandshurica extract on hyperglycemic animal model in Wistar rats 1.1 Test materials
药品 茳芒提取物, 由吉林大学再生医学科学研究所新药研究室提  Medicine Mang Mang extract was extracted by the New Drug Research Institute of Institute of Regenerative Medicine Science of Jilin University
2 2
更正页(细则第 91条) 供, 批号: 20010708; 消渴丸由广州中药一厂生产, 批准文号: (1994) 第 11146号。 Correction page (Article 91) Supply, batch number: 20010708; Xiaoke pills are produced by Guangzhou No. 1 Chinese Medicine Factory, approval number: (1994) No. 11146.
动物 wistar大鼠, 雌雄各半, 体重 195g -240g, 由吉林大学实验动 物部提供,质量合格证号: 医动字第 10-5110号; 主要试剂和仪器 链脲霉素 STZ 美国 sigma化学公司出品, 批号: 89H0604  Animal Wistar rats, male and female, weighing 195g-240g, provided by the Experimental Animal Department of Jilin University, quality certificate number: Yidongzi No. 10-5110; main reagents and instruments Streptozotocin STZ produced by the American sigma chemical company , Lot Number: 89H0604
血糖试条 北京怡成生物电子技术有限公司出品。 Blood glucose test strip produced by Beijing Yicheng Bioelectronic Technology Co., Ltd.
JPS-III型快速血糖测试仪 北京怡成生物电子技术有限公司出品。 JPS-III fast blood glucose tester produced by Beijing Yicheng Bioelectronic Technology Co., Ltd.
离心机 北京医用离心机厂, 型号: LDZ5—2。 Centrifuge Beijing Medical Centrifuge Factory, Model: LDZ5-2.
全自动生化仪 日本日立公司出品, 型号: 日立 7170A型。  Fully automatic biochemical analyzer, produced by Hitachi, Japan, Model: Hitachi 7170A.
1.2试验方法 1.2 Test method
试验条件与方法: Test conditions and methods:
自吉林大学动物部引入 Wistar大鼠后, 饲养于吉林大学基础医学院 动物室, 室温 22-25°C, 湿度 30-60%,饲料组成: 玉米面 39%、 豆饼面 25%、 麦糠面 14%、 高粱面 10%、 骨粉 2.5%、 鱼粉 5%、 酵母 3.5%、 添 加剂 1% 。  Since the introduction of Wistar rats by the Animal Department of Jilin University, they have been kept in the animal room of the Basic Medical College of Jilin University, room temperature 22-25 ° C, humidity 30-60%, feed composition: corn meal 39%, bean cake noodle 25%, wheat bran noodle 14 %, Sorghum noodles 10%, bone meal 2.5%, fish meal 5%, yeast 3.5%, and additives 1%.
取茳芒提取物药粉配成 5.2%(g/v)、 2.6%(g/v)、 1.3%(g/v)大、 中、 小 三个剂量的供试药液。 消渴丸配成浓度为 20%(g/v)供试药液。  Take the mango extract powder to prepare 5.2% (g / v), 2.6% (g / v), 1.3% (g / v) large, medium and small doses of test solution. Xiaoke pill is formulated into a test solution with a concentration of 20% (g / v).
自吉林大学动物部引入 Wistar大鼠 110只,雌雄各半,在本室适应 1 周, 禁食不禁水 4小时后, 称体重、 测血糖、 作标记。 选择血糖值在正 常范围内、状态好的 100只雌雄各半的大鼠做实验, 从中留 10只作为正 常对照组, 将 90只 Wistar大鼠用链脲霉素 STZ按 0.054g/kg造模型, 链 脲霉素 STZ用 0.05mol/L枸椽酸溶液 PH=4.5配成 2.0%的溶液,现用现配。  110 Wistar rats, male and female, were introduced from the Animal Department of Jilin University. They were acclimated in the room for 1 week, fasted for 4 hours, and weighed, measured for blood glucose, and marked. 100 male and female rats with good blood glucose levels in the normal range were selected for experiments, 10 of them were left as normal control groups, and 90 Wistar rats were modeled with streptozotocin STZ at 0.054 g / kg The streptozotocin STZ was formulated into a 2.0% solution with 0.05 mol / L citric acid solution PH = 4.5, and is now used.
3 3
更正页(细则第 91条) 大鼠禁食不禁水 16小时后, 按体重腹腔一次注入链脲霉素 STZ药液。 第 8天禁食不禁水 4小时后, 测血糖, 其中血糖值大于 10mmol/L为模 型成立。 与正常对照组比较有显著性差异 P<0.001。 将 54只高血糖模型 动物, 随机分为五组, 每组 10〜11只, 雌雄各组均分。 分组为: 正常对 照组、 模型组、 消渴丸组 2.0g/kg, 相当于临床用量的 4倍; 茳芒提取物 大剂量组 0.62g/kg、 中剂量组 0.31g/kg、 小剂量组 0.15g/kg, 相当于临床 用量的 8、 4、 2倍。 Correction page (Article 91) After fasting for 16 hours without fasting, rats were injected with streptozotocin STZ solution once intraperitoneally according to their weight. On the eighth day after fasting for 4 hours, the blood glucose was measured, and a blood glucose value of more than 10 mmol / L was established as a model. Compared with the normal control group, there was a significant difference P <0.001. Fifty-four hyperglycemic model animals were randomly divided into five groups, with 10 to 11 animals in each group. The groups are: normal control group, model group, Xiaoke Wan group 2.0g / kg, which is equivalent to 4 times the clinical dosage; mango extract large dose group 0.62g / kg, medium dose group 0.31g / kg, low dose group 0.15g / kg, equivalent to 8, 4, or 2 times the clinical dosage.
模型组给水 10ml/kg, 各给药组均给予 10ml/kg供试药液。 每日上午 9时左右灌胃给药, 连续四周, 每周测血糖、 体重, 按新体重计算药量一 次。 于给药第四周后处死动物, 取血测血常规、血液生化指标、血液流变 学和胰岛素含量,并取胰腺进行病理组织学检查。将各组所得结果以均值 (Ϊ )土标准差 (S)表示, 结果与模型组进行组间 t检验, 判断其显著性。 1.3试验结果  The model group was given 10 ml / kg of water, and each administration group was given 10 ml / kg of test solution. Gavage is administered around 9am every day for four consecutive weeks. Blood glucose and body weight are measured weekly, and the dose is calculated once based on the new weight. Animals were sacrificed after the fourth week of administration, blood tests were performed for blood routine, blood biochemical indicators, blood rheology and insulin content, and pancreas were taken for histopathological examination. The results obtained by each group are represented by the mean (Ϊ) soil standard deviation (S), and the results are compared with the model group to perform a t-test between the groups to determine their significance. 1.3 Test results
1.3.1对血糖的影响  1.3.1 Impact on Blood Sugar
给药后第三周茳芒提取物大剂量组、 中剂量组与模型组比较血糖明 显下降, P<0.05。 第四周茳芒提取物大、 中剂量组和消渴丸组血糖值均 降低, 与模型组比较, 具有明显统计学意义 P<0.05, 见表 1。  At the third week after administration, the blood glucose of the mango extract in the high-dose group, the middle-dose group and the model group significantly decreased, P <0.05. At the fourth week, the blood glucose levels of the large and medium doses of the mango extract were lowered. Compared with the model group, the blood glucose level was significantly statistically significant P <0.05, see Table 1.
4 4
更正页(细则第 91条) §组剂 Correction page (Article 91) § Composition
 the amount
茳芒提取物对高血糖模型大鼠血糖值 (mmol/L)的影响( 士 s) 正常对照组 模型组 消渴丸组 大剂量组 中剂量组 小剂量组 lOml/kg 2. Og/kg 0.62g/kg 0.31g/kg 0.15g/kg Effect of Mang Mango Extract on Blood Glucose (mmol / L) in Hyperglycemic Model Rats (± s) Normal Control Model Model Xiaoke Pill Group Medium Dose Group Low Dose Group 10ml / kg 2. Og / kg 0.62 g / kg 0.31g / kg 0.15g / kg
10 8 9 10 9 8 给药前 6.11 ±0.53 17.52±2.40 17.22±3, 22 17.04±3.34 17.10±2.63 16.34±3.32 一周 6.19±0.50 17.15±2.23 16.84±3.06 15.54±3.23 15.10±2.36 15.72±3.15 二周 6.12±0· 41 15.85±3.02 14.57±3.02 13.59±2.60 14.06±2.53 15.18±3.23 三周 6.22±0.31 14.05 ±3.52 11.97±2.53 10.93±2.58* 10.71±2.72* 13.05±3.26 四周 5.89±0.46 13.80±4.16 9.38±2.83* 9.07±2.78* 9.45 ±1.98* 11.71±3.53 与模型组比较 ,*Ρ〈0.05 10 8 9 10 9 8 6.11 ± 0.53 17.52 ± 2.40 17.22 ± 3, 22 17.04 ± 3.34 17.10 ± 2.63 16.34 ± 3.32 one week 6.19 ± 0.50 17.15 ± 2.23 16.84 ± 3.06 15.54 ± 3.23 15.10 ± 2.36 15.72 ± 3.15 two weeks before administration 6.12 ± 0 · 41 15.85 ± 3.02 14.57 ± 3.02 13.59 ± 2.60 14.06 ± 2.53 15.18 ± 3.23 three weeks 6.22 ± 0.31 14.05 ± 3.52 11.97 ± 2.53 10.93 ± 2.58 * 10.71 ± 2.72 * 13.05 ± 3.26 four weeks 5.89 ± 0.46 13.80 ± 4.16 9.38 ± 2.83 * 9.07 ± 2.78 * 9.45 ± 1.98 * 11.71 ± 3.53 Compared with the model group, * P <0.05
试验例 2 本发明食品治疗糖尿病患者的临床观察 2.1—般资料 见表 2 表 2糖尿病患者饮用茳芒子后的情况  Test Example 2 Clinical observation of the food of the present invention in the treatment of diabetic patients 2.1-General information See Table 2 Table 2
Figure imgf000006_0001
Figure imgf000006_0001
5  5
更正页 (;细则第 91条) 2.2、 治疗结果 Correction page (; Article 91) 2.2 Treatment results
2.2.1本发明的降糖效果极显著  2.2.1 The glucose-lowering effect of the present invention is extremely significant
从表 2可明显看出, 这 25名糖尿病患者经 28天饮用, 除 2名患者 出现腹泻和周身不适以外, 其余都有较明显降糖效果, 服用后和服用前 比较血糖值平均降低 2.0mmol/L, 重症患者降低 14.1mmol/L。 经 t测验 分析, t值 =3.161, 在自由度 N=N-1=23-1=22时, p=0.01的 t=2.819, 所 以降糖效果极显著。  It can be clearly seen from Table 2 that these 25 diabetic patients consumed it for 28 days. Except for 2 patients who had diarrhea and general discomfort, the others had a significant hypoglycemic effect. After taking and comparing the blood glucose level, the average blood glucose was reduced by 2.0mmol. / L, reduced by 14.1mmol / L in severe patients. After t-test analysis, the t-value = 3.161, and at the degrees of freedom N = N-1 = 23-1 = 22, p = 0.01 and t = 2.819, so the effect of reducing glucose is extremely significant.
2.2.2饮用时间越长, 效果越好  2.2.2 The longer you drink, the better the effect
2.2.2.1饮用一周显效情况如表 3 :  2.2.2.1 The results of one week of drinking are shown in Table 3:
饮用一周降糖效果分析  Analysis of hypoglycemic effect after drinking for a week
Figure imgf000007_0001
Figure imgf000007_0001
6 6
更正页(细则第 91条) 根据表 3进行1测验, 其结果: t=l,962, 当自由度 N-l=22-l=21时, P-0.05的 t=2.080, p==0.10的 t=1.721, 所以饮用一周虽有效果但不显著。 2.2.2.2饮用二周效果分析如表 4: Correction page (Article 91) Test 1 according to Table 3, the results are: t = l, 962, when the degree of freedom Nl = 22-l = 21, t = 2.080 for p-0.05, t = 1.721 for p == 0.10, so although drinking one week The effect is not significant. 2.2.2.2 The analysis of the effect of drinking for two weeks is shown in Table 4:
表 4 饮用二周降糖效果分析  Table 4 Analysis of hypoglycemic effect after drinking for two weeks
Figure imgf000008_0001
Figure imgf000008_0001
t测验结果, t=2,2637,当自由度 N=N-1=22-1=21时, p=0.05的 t=2.080, p=(U0的 t=2.831, 所以差异显著, 即效果明显。  t test results, t = 2,2637, when the degrees of freedom N = N-1 = 22-1 = 21, p = 0.05, t = 2.080, p = (U0's t = 2.831, so the difference is significant, that is, the effect is obvious .
2.2.2.3饮用三周效果分析如表 5:  2.2.2.3 The effect analysis after drinking for three weeks is shown in Table 5:
更正页(细则第 91条) 表 5 饮用三周降糖效果分析 Correction page (Article 91) Table 5 Analysis of hypoglycemic effect after drinking for three weeks
Figure imgf000009_0001
Figure imgf000009_0001
t测验结果, t=2.5043,当自由度 N=N-1=19-1=18时, p=0.05的 t=2.101 p=0.01的 t=2.878, 所以效果显著。  t test result, t = 2.5043, when the degree of freedom N = N-1 = 19-1 = 18, p = 0.05 t = 2.101 p = 0.01 t = 2.878, so the effect is significant.
2.2.2.4 饮用四周效果分析如表 6:  2.2.2.4 The analysis of the effects of drinking for four weeks is shown in Table 6:
8 8
更正页(细则第 91条) 饮用四周降糖效果分析 Correction page (Article 91) Analysis of hypoglycemic effect after drinking
Figure imgf000010_0001
Figure imgf000010_0001
经 t测验结果, t=3.161,当自由度 N=N-1=22-1=22时, p=0.05的 t=2.074, p=0.01的 t=2.819, 所以效果极显著。  According to the t test result, t = 3.161, when the degrees of freedom N = N-1 = 22-1 = 22, p = 0.05 and t = 2.074, p = 0.01 and t = 2.819, so the effect is extremely significant.
通过分析得出, 糖尿病患者饮用本发明, 饮用时间越长, 效果越明 显, 即饮用一周基本无效, 饮用两周显现降糖效果, 饮用三周降糖效果 显著, 饮用四周后降糖效果极显著。  According to the analysis, the diabetic patients drink the invention, the longer the drinking time, the more obvious the effect, that is, drinking for one week is basically ineffective, drinking for two weeks shows a hypoglycemic effect, drinking for three weeks has a significant hypoglycemic effect, and drinking for four weeks is extremely significant .
2.2.3患病年限与饮用效果分析  2.2.3 Analysis of disease duration and drinking effect
将表 1中 23名饮用本发明的糖尿病患者分成两组:患病 5年以上的 为一组, 患病 4年以下的为一组, 进行统计分析, 其结果:  The 23 diabetes patients drinking the invention in Table 1 were divided into two groups: those with disease for more than 5 years as a group, those with disease for less than 4 years as a group, and statistical analysis was performed, and the results were as follows:
9  9
更正页(细则第 91条) 2.2.3.1、 患病 5年以上的效果分析如表 7 Correction page (Article 91) 2.2.3.1. The analysis of the effect for more than 5 years is shown in Table 7.
表 7 患病 5年以上的饮用效果分析  Table 7 Analysis of drinking effects for more than 5 years
Figure imgf000011_0001
Figure imgf000011_0001
t测验结果, t=1.782,当自由度 N=N_ 1=13— 1=12时, p=0.05的 t==2.197, p=0.01的 t=1.782, 所以效果并不显著。  t test result, t = 1.782, when the degrees of freedom N = N_ 1 = 13—1 = 12, t == 2.197 at p = 0.05, and t = 1.782 at p = 0.01, so the effect is not significant.
2.2.3.2、 患病 4年以下的饮用效果分析如表 8 2.2.3.2. Table 8 shows the analysis of drinking effects for patients under 4 years of illness.
患病 4年以下的饮用效果分析  Analysis of drinking effects under the age of 4 years
Figure imgf000011_0002
Figure imgf000011_0002
t测验结果, t=2.966,当自由度 N=N—1-10—1=9时, p=0.05的 2.262, p=0.01的 t=3.250,所以 效果显著。  t test result, t = 2.966, when the degree of freedom N = N—1-10—1 = 9, p = 0.05 of 2.262, p = 0.01 of t = 3.250, so the effect is significant.
10  10
更正页(细则第 91条) 2.3结论 Correction page (Article 91) 2.3 Conclusion
1、 茳芒子对糖尿病患者降血糖有显著效果。  1. Amaranth has a significant effect on reducing blood sugar in patients with diabetes.
2、 糖尿病患者饮用茳芒子两周即可显效, 四周效果显著。  2. Diabetic patients can take two weeks to drink it, and the effect is obvious around four weeks.
3、 患病时间短 (4年以下) 比时间长 (5年以上)饮用茳芒子效果 好。  3. The illness time is shorter (less than 4 years) and longer than that (more than 5 years).
以下通过实施例来进一步阐述本发明食品的制备。  The following examples further illustrate the preparation of the food of the present invention.
实施例 1  Example 1
一种含有茳芒子水提取物用以改善糖尿病症状的保健口服液 茳芒子水提取物 2.0g,水 10000ml,混合后装入 100 支瓶中, 每支 100ml, 含茳芒子提取物 20mg。  A health-care oral liquid containing mangosteen water extract to improve the symptoms of diabetes 2.0g of mangosteen water extract, 10000ml of water, mixed into 100 bottles, each 100ml, containing 20mg of mangosteen extract .
实施例 2  Example 2
一种含有茳芒子的可改善糖尿病症状的袋泡茶  Teabag containing mangosteen which can improve symptoms of diabetes
茳芒子 20.0g,将苦丁茶粉碎成 L5〜2mm的碎粒 4980g, 二者充分混 合, 装入食品袋中, 制成 500袋, 每袋重 10g,含茳芒子 40mg。  Mangosteen 20.0g, kudingcha was pulverized into 4980g of L5 ~ 2mm pieces, and the two were thoroughly mixed and put into a food bag to make 500 bags. Each bag weighed 10g and contained mangosteen 40mg.
实施例 3  Example 3
一种含有茳芒子水提取物可改善糖尿病症状的饮料  Beverage containing amaranth extract to improve diabetes symptoms
茳芒子水提取物 lO.Og,刺梨汁 1000L混合后装瓶 1000瓶, 每瓶 1L, 每瓶含茳芒子水提取物 10mg。  Water extract of mangosteen 10g, mixed with 1000L of prickly pear juice and packed into 1000 bottles, 1L per bottle, each bottle contains 10mg of water extract from mangosteen.
实施例 4  Example 4
一种含有茳芒子可改善糖尿病症状的食品  Food containing mangosteen to improve diabetes symptoms
茳芒子水提取物 10g,面粉 1000g, 风味剂 lg,酵母 lg, 盐 2g, 作为 原料, 加水和面, 醒发, 烘烤, 冷却, 包装。  Mangosteen water extract 10g, flour 1000g, flavor lg, yeast lg, 2g salt, as raw materials, add water and flour, proof, bake, cool, and package.
11 11
更正页(细则第 91条)  Correction page (Article 91)

Claims

权 利 要 求 书  Request for Rights
、 茳芒在制备改善糖尿病症状的食品中的应用 And stalk in the preparation of food to improve the symptoms of diabetes
、 茳芒水提取物在制备治疗糖尿病及改善其症状的食品中的应用 ° Application of Amaranth water extract in the preparation of food for treating diabetes and improving its symptoms °
12 12
更正页(细则第 91条)  Correction page (Article 91)
PCT/CN2003/001011 2003-11-24 2003-11-24 Use of cassia sophera and its aqueous extract for producing foods of reducing symptom of diabetic WO2005048738A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/CN2003/001011 WO2005048738A1 (en) 2003-11-24 2003-11-24 Use of cassia sophera and its aqueous extract for producing foods of reducing symptom of diabetic
CNA2003801102568A CN1764390A (en) 2003-11-24 2003-11-24 Cyperus awns and extract thereof improve the Application in Food of diabetic symptom in preparation
AU2003289600A AU2003289600A1 (en) 2003-11-24 2003-11-24 Use of cassia sophera and its aqueous extract for producing foods of reducing symptom of diabetic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2003/001011 WO2005048738A1 (en) 2003-11-24 2003-11-24 Use of cassia sophera and its aqueous extract for producing foods of reducing symptom of diabetic

Publications (1)

Publication Number Publication Date
WO2005048738A1 true WO2005048738A1 (en) 2005-06-02

Family

ID=34596930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2003/001011 WO2005048738A1 (en) 2003-11-24 2003-11-24 Use of cassia sophera and its aqueous extract for producing foods of reducing symptom of diabetic

Country Status (3)

Country Link
CN (1) CN1764390A (en)
AU (1) AU2003289600A1 (en)
WO (1) WO2005048738A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1240115A (en) * 1999-05-18 2000-01-05 潘世全 Cassia sophera hypoglycemic thirst-quenching beverage and productive process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1240115A (en) * 1999-05-18 2000-01-05 潘世全 Cassia sophera hypoglycemic thirst-quenching beverage and productive process

Also Published As

Publication number Publication date
CN1764390A (en) 2006-04-26
AU2003289600A1 (en) 2005-06-08

Similar Documents

Publication Publication Date Title
JP6271571B2 (en) Composition for maintaining intestinal microbiota equilibrium, process for producing the composition, and use of the composition
KR100750988B1 (en) Composition having ginsenosides for treating or preventing diabetes
KR100937455B1 (en) Bowel movement promotion functional food containing psyllium seed, rice bran fermentation extracts and yeast extracts and manufacturing method thereof
CN107950851A (en) One kind is without bitter taste complex polypeptide powder
CN111544550B (en) Traditional Chinese medicine formula flora capsule, preparation method and application in preparation of medicine for treating type 2 diabetes
CN106723015A (en) A kind of health food and its preparation technology with antifatigue and anti-oxidation function
CN109069562A (en) Polysaccharide digests inhibitor
CN105725187A (en) Blood sugar reducing composition and application in preparation of foods and health-care foods
CN104288344B (en) Application of Pu&#39; er tea extract in preparation of medicine or food for regulating intestinal flora and relaxing bowels
JP2007230969A (en) Ameliorant for metabolic syndrome
CN111317775A (en) Application of preparation for removing food retention and relieving cough for children in preparation of medicine for treating fever and preparation method thereof
CN103920140B (en) A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation
CN108420890B (en) Composition with blood fat reducing effect and preparation method thereof
JP6976030B2 (en) Composition for prevention or improvement of non-alcoholic fatty liver disease
CN103610048B (en) To chemical damage health food having assistant protection function and preparation method thereof
KR101876534B1 (en) Composition for preventing or improving nonalcoholic fatty liver disease
CN114794277A (en) Tea composition with effects of reducing fat, reducing blood sugar and reducing uric acid and application thereof
WO2014134833A1 (en) Edible composition, preparation method therefor, and food product comprising the composition
CN114533817A (en) Composition for improving blood sugar and/or blood fat and application thereof
WO2005048738A1 (en) Use of cassia sophera and its aqueous extract for producing foods of reducing symptom of diabetic
WO2013013500A1 (en) Radix puerariae and semen litchi drink for reducing blood glucose and preparation method thereof
KR101330687B1 (en) Composition for treating and preventing obesity containing oriental herbal extracts
CN112206283A (en) Traditional Chinese medicine composition for relieving physical fatigue and preparation method thereof
CN113813331A (en) Composition with throat clearing function and preparation method and application thereof
CN107029092A (en) A kind of mare&#39;s milk sugar-reduction traditional Chinese medicine composition and its preparation method and application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 20038B02568

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP